DoW Peer Reviewed Cancer, Clinical Trial Award
🏛 Defense Health Agency Contracting Activity - DHACA (DOD-AMRAA)
✓ Free, no account · Source: Grants.gov · Last verified Jul 27, 2026
Can you apply?
This grant is for researchers conducting clinical trials on cancer treatments and interventions. Eligible applicants are typically academic medical centers, research institutions, hospitals, and nonprofit research organizations with capacity to conduct FDA-regulated clinical trials. Applicants must have institutional biosafety and regulatory expertise. Trials can range from small proof-of-concept (phase 0) to large-scale efficacy studies (phase III). All preclinical work must be completed before the award begins. Projects must align with one of the FY26 PRCRP topic areas.
Not the right fit? Find grants for your organization in 5 questions →
Program description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Distinctive Features:
• Applications to this award mechanism must include a clinical trial.
• Projects can range from phase 0 to phase III.
• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.
• Applications are required to include patient advocates.
• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Federal Application for Grant Assistance)
- Project Narrative/Research Plan
- Budget and Budget Justification
- IRB Approval (or evidence of IRB review)
- IND/IDE Application (if applicable)
- Patient Advocate letters of commitment
- Institutional Biosafety Committee approval or documentation
Program contact
- 👤 Abigail Strock Contract Specialist
- 📧 help@eBRAP.org
- 📞 3016192342
Funding track record
Recent awards under CFDA 12.420 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$2,265,729,366
-
$800,631,761
-
$74,531,880
-
$67,205,571
-
$55,443,120
-
$34,191,124
-
$24,783,894
-
$21,394,379
-
$19,100,256
-
$19,002,641
Top States by Funding
- MD 10 awards $3,150.1M
- NC 11 awards $132.3M
- CA 12 awards $107.3M
- FL 8 awards $99.8M
- MA 8 awards $83.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 12.420). How funding has trended year over year.
| 2024 | $1,483,968,520 | |
| 2025 | $1,201,153,417 |
FAQ
Who can apply for this grant?
Academic medical centers, research institutions, hospitals, and nonprofits with clinical trial infrastructure are eligible. International organizations and small businesses may also apply depending on their structure.
Is a clinical trial required?
Yes. All applications must include a clinical trial as the core project activity. Preclinical work must be completed before the award starts.
What are the deadline and funding range?
The deadline is October 5, 2026. The total funding pool is $45 million, but individual award amounts are not specified in this program.
Can I include animal studies?
No. Animal studies are not allowed under this award. All preclinical work must be completed before the award begins.
Do I need regulatory approval before applying?
If your trial requires an IND, IDE, or equivalent, the regulatory application must be submitted to the FDA by the application deadline.
💡 Tips for applicants
- Include patient advocates on your team. The program requires meaningful patient engagement in trial design and conduct.
- Clearly map your proposed trial to one of the FY26 PRCRP topic areas. Misalignment with priorities will weaken your application.
- If regulatory approval is needed, submit IND/IDE applications early. Do not wait until the deadline.
- Demonstrate rapid implementation capacity. The program prioritizes trials that can launch and enroll quickly.
- Include a realistic timeline and enrollment plan. Overly ambitious timelines or vague recruitment strategies are red flags.
⚠️ Common mistakes
Submitting animal studies or preclinical research instead of clinical trials. Failing to include meaningful patient advocates or community stakeholder input. Misaligning the proposed trial with FY26 PRCRP topic areas.
Similar grants
- OPEN DoW, Peer Reviewed Cancer, Impact Award — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Peer Reviewed Cancer, Idea Award — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Breast Cancer, Breakthrough Award Level 3 — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Breast Cancer, Breakthrough Award Level 4 — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Lung Cancer Translational Research Award — Defense Health Agency Contracting Activity - DHACA